breaking news

Monoclonal Antibody Infusion

Monoclonal Antibody Infusion is a therapy granted by the FDA’s Emergency Use Authorization (EUA) as a treatment for severe COVID-19 symptoms in patients at high risk of hospitalization.

Monoclonal Antibody Infusion is available now for patients who meet the following requirements:

  1. You have a positive COVID-19 test result
  2. You are not already hospitalized
  3. You have mild-to-moderate symptoms that started less than 10 days ago
  4. You have certain medical conditions or other health factors that place you at a higher risk of progressing to a severe infection:
    • Age 65 years or older
    • Obese or over weight which may include a Body Mass Index (BMI) of 25 or higher for adults or a BMI in the 85th percentile or higher on the growth chart for pediatric patients.
    • Pregnant
    • Diabetes
    • Chronic kidney disease
    • Immunosuppressive disease, or on immunosuppressive treatment
    • Cardiovascular disease (including congenital heart disease) or hypertension
    • Chronic lung disease such as chronic obstructive pulmonary disease (COPD), moderate to severe asthma, cystic fibrosis, or pulmonary hypertension)
    • Sickle cell disease

Related Links

https://abc3340.com/news/local/alabama-facing-cutback-of-monoclonal-antibody-treatments-from-federal-suppliers

https://www.cbsnews.com/news/monoclonal-antibodies-covid-19-patients/

https://www.cbsnews.com/news/monoclonal-antibodies-covid-19-treatment-florida-texas-states/

https://www.miamiherald.com/news/coronavirus/article254397879.html

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab

One thought on “Monoclonal Antibody Infusion

Leave a Reply

Your email address will not be published.